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INTRODUCTION
In an effort to understand the correlates of protective immunity to human immunodeficiency virus type 1 (HIV-1) infection, marked attention has been given to the small group of HIV-1 long-term nonprogressors (LTNP) and elite controllers that either do not develop disease or do so with slower pace 1, 2 . However, less attention has been given to individuals infected with HIV-2, an infection that is compatible with normal lifespan in most infected individuals and, if disease develops at all, progression rate is lower than in HIV-1 infection 3 . Also vertical and heterosexual transmission of HIV-2 occurs less frequently than with HIV-1 [4] [5] [6] . Moreover, a recent study found that HIV-1 disease progression was inhibited by concomitant HIV-2 infection 7 . Although the underlying mechanisms behind differences between HIV-1 and HIV-2 infections remain to be clarified, viral replication and the envelope glycoprotein complex (Env) characteristics could be important. Indeed, similar levels of proviral load but approximately one log lower plasma virus load in HIV-2 infection compared to HIV-1 infection could indicate more effective control of viral replication in HIV-2 infection [8] [9] [10] [11] . In addition, the HIV-2 Env seems to
have a more open configuration characterized by multiple broadly cross-reactive epitopes and reduced CD4 dependence, which are uncommon characteristics of HIV-1 12, 13 . Moreover, as shown in our earlier work, HIV-2-infected individuals display plasma with potent neutralizing activity (NAc) against HIV-2 isolates (intratype neutralization), whereas NAc of HIV-1 plasma against HIV-1 isolates is of lower magnitude 14 .
The magnitude and frequency of virus specific serum immunoglobulin A (IgA) has been studied and found to be low in chronic HIV-1 infections in HIV-1 infected chimpanzees as well as in
SIV-infected rhesus macaques [15] [16] [17] [18] . The knowledge on HIV-2 specific serum IgA is limited, and to our knowledge, only one study reports on neutralization by IgA in HIV-2 infection 19 .
HIV-1 is mainly a mucosal pathogen targeting CD4+CCR5+ memory T cells abundantly present in gut-associated lymphoid tissue (GALT) 20 . The predominant antibody isotype in GALT is IgA.
Interestingly, in humans, including HIV-1 infected cases, it has been shown that part of mucosal
IgA is also secreted directly into the blood [21] [22] [23] . Furthermore, it is known that a large proportion of the circulating antibody secreting cells (ASC) express IgA and most of them are derived from mucosal immune reactions 16, 24, 25 . IgA may also display anti-inflammatory effects mediated by FcαRI binding 26, 27 . Instead, effector functions beyond binding to antigen and classical neutralization, i.e. complement activation and induction of phagocytosis, has been reported to be a minor feature of IgA 28, 29 .
In the present study, we examined, side by side, the neutralizing activity of This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. 
MATERIALS AND METHODS

Study Population
Women attending the Agiubef sexual health and family planning clinic for urogenital problems in Bissau, Guinea-Bissau from November 2006 to January 2011 were invited to participate in the study. After informed consent, HIV test counseling was given. Subsequently, a blood sample was drawn and, general and gynecological examinations were performed. At the clinics, all women were offered free treatment for the diagnosis of other sexually transmitted diseases and condoms. In this screening, including 1287 individuals, women with HIV-1 (n=47), HIV-2 (n=21) and HIV-D (n=22) infections were identified and after one more blood sampling, referred to HIV treatment and support centers. For the current study, 10 HIV-1, 10 HIV-2 and 8 HIV-D infected women were selected on the basis of CD4+ T cell count availability ( Table 1 ). The study participants were further characterized by assessment of age, plasma viral load and plasma total IgG and IgA levels ( Table 1) . None of the study participants received anti-retroviral treatment at the time of blood sampling. HIV-negative controls (n=16) were selected on the basis of plasma sample availability.
Blood Sampling, HIV-1, HIV-2 Status and CD4+ T cell Determination
Venous blood samples were drawn and collected in vacutainer tubes (BD Biosciences, San Jose, CA) with EDTA as anti-coagulant. Plasma was then kept frozen at -80º C until use in neutralization assays, viral load determinations and other laboratory analyses. Serological testing for HIV-antibodies was done using the Behring Enzygnost HIV-1/HIV-2 ELISA (Behring, Marburg, Germany). Confirmation and differential HIV-1/HIV-2 diagnoses were performed
using Capillus HIV-1/HIV-2 (Cambridge Biotech Limited, Galway, Ireland), and Immunocomb II HIV-1 and HIV-2 BiSpot RST (Origenics, Yavne, Israel). CD4+ T cell counts were determined by flow cytometry using the CyFlow instrument (Partec GmbH, Münster, Germany) and the CD4% antibody kit (CyTecs GmbH, Görlitz, Germany) according to the manufacturer's instruction.
HIV Plasma Viral Load
Viral RNA was extracted and purified from 200 µl blood plasma samples, using RNeasy Lipid This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. 
Assessment of IgG and IgA Levels
IgG levels in plasma were measured by an in-house ELISA 13 found not to exceed 0.1µg/ml.
IgA Purification from Non-IgG Plasma Fraction
IgA was purified from non-IgG fractions of plasma using peptide M/Agarose gel slurry This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
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temperature for 30 min. After incubation, the column was washed and the flowthrough fractions were collected. The bound antibodies were then eluted with IgG elution buffer (6x200 µl, Thermo Scientific, Rockford, IL) and neutralized immediately with neutralization buffer (6x20 µl 1 M Tris-HCl pH 9.0) (GE Healthcare Life Sciences). The column was subsequently regenerated by washing with regeneration buffer (2x300 µl PBS with 20% ethanol) and used for another round of purification of the flowthrough to increase the yield. Finally, the eluted fractions from the two consecutive purification processes were combined, buffer exchanged with PBS, and concentrated using Amicon Ultra-15 centrifugal filter units with a 30.000-Da cutoff (Merck Millipore). Purified IgAs were kept at 4°C until use. Residual IgG in the IgA fraction was assessed by IgG ELISA, as described above, and found not to exceed 0.1µg/ml.
Primary HIV-1 and HIV-2 Isolates
For the analysis of neutralizing activity ( intra-assay variation was repeatedly found to be less than 10%, a 30% reduction in fluorescent PFU, corresponding to >3 SD, was chosen as cut-off 37 . Reduction of PFU by negative control plasma Ig, tested individually from six HIV uninfected subjects, was repeatedly below 30% (data not shown).
Magnitude of Plasma IgG and IgA Neutralizing Activity
For analysis of the magnitude of plasma Ig NAc, plasma Ig was titrated against one HIV-1 and one HIV-2 isolate. The magnitude of NAc in an individual plasma Ig was determined by its neutralization score defined as log-transformed titers 38 . Log-transformed titers were calculated by dividing the highest dilution giving neutralization by 100 before applying a log-base 3 transformation and then adding 1 [Y=log3 (dilution/100)+1]. All titers below 1:40 were given a value of 33 for the sake of calculation of a neutralization score.
HIV-Specific Neutralizing Activity in Relation to Total Plasma IgG and IgA
For determination of proportions of IgG and IgA with specific, i.e. neutralizing activity, the reciprocal intratype neutralizing titer of plasma IgG and IgA were related to total plasma IgG and IgA levels. Reciprocal intratype neutralizing titer of plasma IgG and IgA were divided by the amount of IgG and IgA, respectively, present in 150µl, corresponding to the volume assessed in neutralization assay setup (see above). This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Statistical Methods
13
For comparisons between unrelated categorical variables, Fisherś exact test was used.
Differences between independent subgroups of numerical variables were assessed by Mann 
Ethical Considerations
The This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
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RESULTS
Neutralization of HIV-1 and HIV-2 by Plasma IgG and IgA
To study neutralizing activity mediated by plasma IgG and IgA in HIV-1 and HIV-2 infections, neutralization of one HIV-1 and one HIV-2 isolate was assessed in a plaque reduction assay.
Purified IgG and IgA were tested in dilution steps starting from the concentration corresponding to a 1:20 plasma dilution. IgG from HIV-1 infected individuals showed moderate level neutralization of the HIV-1 isolate (intratype neutralization), similarly to our previous experience with HIV-1 plasma, median reciprocal titer 50 ( Table 2) . Neutralization of the HIV-2 isolate with HIV-1 IgG (intertype neutralization) was of similar level, median reciprocal titer 60, with the exception of IgG of two plasma (Table 2 ). In contrast, intratype neutralization mediated by HIV-2 plasma IgG was found to be stronger, median reciprocal titer 163840 ( 
Neutralization by IgG and IgA Derived From HIV-D Plasma
For the purpose of analyzing HIV-1 and HIV-2-directed neutralizing antibody responses generated within the same host we tested IgG and IgA purified from plasma of HIV-D individuals. Results showed that HIV-D IgG neutralized both the HIV-1 and HIV-2 isolates (Table 2) . Furthermore, the magnitude of HIV-2 directed IgG neutralization was found to be higher than that of HIV-1 directed IgG (p<0.001) ( Figure 1A ). In fact, the magnitude of HIV-1 neutralization was similar to that seen with plasma IgG from HIV-1 singly infected. HIV-D IgA did not neutralize the HIV-1 isolate, with the exception of IgA from one plasma, similarly to HIV-1 IgA, but neutralized the HIV-2 isolate as frequently and potently as IgA from HIV-2 singly infected (Table 2 and Figure 1 ). Taken together, this indicates that type of virus play role in eliciting the frequency and strength of neutralization by both plasma IgG and IgA.
IgG and IgA Intratype Neutralizing Activity in Relation to Total Plasma IgG and IgA
For the analysis of proportions of IgG and IgA with specific activity, i.e. neutralizing capacity, in plasma of HIV-1 and HIV-2 infected individuals the total plasma levels of IgG and IgA were determined. It was noted that plasma IgG levels varied depending on the type of HIV infection. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. to differ in neutralization sensitivity. Therefore, isolates to be used in the present study were selected based on our previous experience 14 . HIV-1 C Br was in our earlier study found to be the most sensitive HIV-1 isolate in neutralization assays using HIV-1 plasma from Guinea-Bissau.
We also avoided use of the most neutralization sensitive HIV-2 isolate, thereby bringing virus sensitivities closer to each other. Interestingly, we noted that intertype neutralization by plasma
IgG was significantly stronger in HIV-1 than HIV-2 infection. Also in this case, the overall higher neutralization sensitivity of HIV-2 may provide an explanation 14, 39, 40 . The difference in frequency of neutralization sensitive virus variants in HIV-1 and HIV-2 infections is further revealed by previous studies of ours and others 14, 39, 40 and goes along with studies showing that escape from neutralizing antibodies is rare in HIV-2 infection while common in HIV-1 infection 13, 35, 42 .
Interestingly, our findings also revealed that the magnitude of IgG, as well IgA intratype neutralization in relation to the level of plasma IgG and IgA was higher in HIV-2 than HIV-1 infection. Thus, despite the fact that HIV-1 plasma contained elevated levels of IgG the virus specific effector function was not increased, but rather appear to be diluted. It is well known that progressive HIV-1 infection is characterized by chronic immune activation, including aberrant cytokine secretion and unspecific activation of T and B cells 43, 44 . Chronic B cell immune activation, is also characterized by manifestation of hypergammaglobulinemia in parallel with disease progression 45 . In line with this, the present study showed that IgG levels in plasma of HIV-1 infected, either singly or dually infected, were elevated as compared with HIV-negative individuals, while HIV-2 plasma IgG was not. This despite the unexpected observation that four out of 10 HIV-2 infected individuals had CD4+ T cell count <200/µl, while this low CD4 count This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
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was only recorded for one out of the 10 HIV-1 positive participants. A finding that might be explained by the fact the participants in the current study had attended a sexual health and family planning clinic for urogenital problems, some of which could be AIDS defining. Nevertheless, we also noted that none of the HIV-2 infected, where plasma viral load could be assessed, displayed plasma viral RNA above 281 copies/ml. This observation together with observations of others suggests that the low degree of immune activation present in HIV-2 infection is associated with the relatively low level of plasma viral load 46, 47 . Thus, it is even more intriguing that both IgG and IgA, of HIV-2 infected individuals display potent intratype neutralizing activity in the absence of strong antigenic stimulation. However, the magnitude of intratype IgG neutralization appeared elevated with severity of HIV-1 disease, here detected as decreasing CD4+ T cell counts, while this was not the case in HIV-2 infection.
It is known that HIV-1 preferentially infects CD4+CCR5+ memory T cells in GALT, and thereby affects the structure of germinal centers in this tissue. Since GALT hosts ASC that almost exclusively secrete IgA, defects in the ability to generate high-affinity HIV-1 specific IgA may be the result 48, 49 . Although the extent of GALT involvement and lymphocyte depletion in Presence of powerful IgA-mediated neutralization in the presence of intact gut mucosa in HIV-1 infected LTNP also supports this hypothesis 50, 51 .
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Monomeric serum IgA has been described as an antibody isotype with anti-inflammatory properties 27, 52, 53 inasmuch it lacks complement-activating capacity and suppresses chemotaxis, phagocytosis, as well as cytokine release 29, [54] [55] [56] . We speculate that blunting of inflammatory processes via anti-HIV-2 plasma IgA may contribute to the lower immune activation in HIV-2 infection.
Taken together, HIV-2 displays features that allow potent intratype neutralization by both IgG This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. 
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